August 17, 2016 08:53 AM EDT
R&D

Split the pot? Ra­dius shows its os­teo­poro­sis cards in fi­nal block­buster match with Am­gen

John Carroll

Editor & Founder

Ra­dius Health $RDUS has tak­en an­oth­er big leap down the fi­nal stretch of its Phase III race with Am­gen $AMGN, post­ing Phase III re­sults that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times